

## FDA Electronic Submissions Gateway (ESG)

# Transparency & Modernization

### Presented by:

Lowell Marshall, ESG Program Manager

Office of Information Management Technology (OIMT)


Office of Digital Transformation (ODT)

Office of the Commissioner (OC)



- 1. Describe what ESG is and how it is used today
- 2. Review how ESG collaborates and communicates with Industry
- 3. Illustrate how ESG has grown over the years, and
- 4. Outline plans for current ESG enhancements
- 5. ESG Next Gen future vision

**ESG Today** 



Per PDUFA: FDA and industry will collaborate to plan and conduct meetings, review initiatives, and engage industry to provide feedback and/or participate in pilot testing prior to implementing significant changes that impact industry's interaction with the ESG. Annually, FDA leadership and PDUFA IT leadership will review initiatives and provide opportunity for Industry input.

## **ESG Transparency and Collaboration (cont'd)**



- Continue to Participate in PDUFA Quarterly
  Industry meetings
- Continue to Participate in FDA and PDUFA leadership meetings
- Continue collaborative activities with Industry for impactful system and software changes


Per PDUFA: "Annually, FDA will provide on the ESG website historic and current metrics on ESG performance in relation to published targets, characterizations and volume of submissions, and standards adoption and conformance."

- Submission Times / Business and Non-Business Hours
  <u>Submission Times | FDA</u>
- Monthly / Annual Metrics
  <u>Submission Statistics | FDA</u>

## **ESG Metrics (2015 – 2021)**

Total submissions:	2015	2016	2017	2018	2019	2020	2021
	3,100,970	3,895,669	4,055,342	4,841,844	5,428,492	5,728,006	7,258,031
Total transactions:	2015	2016	2017	2018	2019	2020	2021
	9,209,782	12,082,860	12,333,127	14,596,282	16,898,047	17,917,796	23,218,281

Average Annual Growth 2015-2021					
Submissions	16%				
Acknowledgments	17%				
Data	25%				
Accounts	16%				



ODT I Office of Digital Transformation

Which of the following statements is **NOT** true?

- A. ESG opens the submission file and reviews content for accuracy
- B. ESG delivers the submission file to the FDA Center without opening or reviewing content.
- C. ESG sends a receipt to the submitter to acknowledge the file has been received

Three phases...

## ESG Continued Enhancements 2021 – 2023

## **ESG Enhancements 2021 – 2023**



Phase 1: Account Portal 1.0 and Submission Virus Scanning

## **Target Completion August 2022**

- Deliver new front end portal enhances user experience and automates the onboarding account management process; enables power user account administration
- Implement enhanced enterprise virus scanning software at the Agency level prior to downstream FDA Center submission processing

## ESG Enhancements 2021 – 2023 (cont'd)



Phase 2: ESG Core Technology Refresh / Enhancements

## **Target Completion September 2022**

- Migrate ESG core components to a GovCloud FedRAMP High Infrastructure
- Implement Account Portal 1.1 with enhanced Center user functionality

## ESG Enhancements 2021 – 2023 (cont'd)



## Phase 3: Enhanced ESG Architecture

## Target Completion December 2023

- Explore GovCloud storage technologies as Center system repositories can accommodate
- Modernize the ESG submission receipt process with cloud-native technologies



What's next???

Continue modernization through PDUFA VII Commitments and other FDA Strategic Initiatives (*aka Next Generation ESG*)



## PDUFA VII:

- FDA will advance the ESG cloud-based modernization with an improved architecture that supports greatly expanding data submission bandwidth and storage, while continuing to ensure its stable operation
- By the end of FY 2025, FDA will complete ESG transition to the cloud, including set-up and integration of an enterprise Identity and Access Management solution that will streamline applicant access to FDA resources.

<u>FDA</u> <u>Strategic</u> <u>Initiatives</u>:

Technology Modernization Action Plan (TMAP)

- Modernization of FDA's technical infrastructure;
- Enhancing FDA's capabilities to develop technology products to support its regulatory mission; and
- Communication and collaboration with stakeholders to drive technological progress that is interoperable across the system and delivers value to consumers and patients

#### Data Modernization Action Plan (DMAP)


- Identify and execute high value driver projects for individual centers and for the Agency;
- Develop consistent and repeatable data practices across the Agency; and
- Create and sustain a strong talent network combining internal strengths with key external partnerships

#### Enterprise Modernization Action Plan (EMAP)

- Create the infrastructure to support change;
- Develop a common operational approach;
- Ensure strategic alignment

## **Next Generation ESG Vision**

To provide the FDA with a **trusted**, **secured cloud-based**, **and unified submission gateway** that is highly available, scalable, and accept a variety of electronic submissions for processing by line-, or subject-specific, business processes.



## **NG ESG Business Process Improvements**



Streamline manual user onboarding process by using modern intelligent business process management platform and ICAM solutions

#### **Improve Customer Experience**

Reduce HelpDesk calls and improve customer experience by using CRM tool to provide updates on submission status and enable two-way communications between centers and users

#### Improve File Transfer Process

Increase file submission processing speed, support file resume transfer function, handle large file sizes, and reduce the complexity in generating the proper submission packages

#### **Improve User Management Process**

Consolidate users accounts and manual access management functions into a unified Enterprise Identity, Credential, and Access Management (ICAM) solution for end users

#### Support New Use Cases

Ensure future capabilities of ESG NG by incorporating new technologies that can support future use cases

#### **ODT I Office of Digital Transformation**

Summary of the

Objectives

## How many phases are included in the ESG's 2021-2023 enhancement effort?

- A. One
- B. Two
- C. Three
- D. Four

## **ESG Transparency and Collaboration - Summary**

- Current ESG has been the FDA central intake portal since 2005
- Since 2015, annual average increase of 17% in submission volume and data size
- Modernize ESG to accommodate a continued rate of growth well into the future

The current ESG has served us well; however, as technologies and user requirements change, the FDA is assertively taking actions to assure ESG will meet future industry, technology, security, and public requirements.

## Questions?

## Lowell Marshall lowell.marshall@fda.hhs.gov

Office of Information Management Technology (OIMT) Office of Digital Transformation (ODT) Office of the Commissioner (OC)

